RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Thanks Ombow. In the Montreal Conf presentation, he first revealed getting back the ex-N.Amer rights from Servier, and then discussed his expectation to do an out-licensing and development deal for the high impact line with a major BP. So I assume it will be done as a package -- global Neurodegenerative rights along with some high impacts (plus some annual money for continued high impact R+D). It just seems like $5-10 mil for such a deal, if that's what it turns out to be, is chicken feed. Such a deal could be much larger once a high impact is in the clinic. The only reason to do it now rather than later is - 1) Cortex is running on fumes, and 2) Stoll wants to in-license the non-Ampakine programs. We can't do much about #1, but we can completely avoid #2 by simply not doing it now.